Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma.
Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma.
复制标题
骨钙素和骨连接蛋白免疫反应性在骨肉瘤诊断中的应用。
DOI：
10.1093/ajcp/108.4.464
复制
发表时间：
1997
影响因子：
3.5
通讯作者：
Tracy,RP
中科院分区：
文献类型：
--
作者：
Fanburg,JC;Rosenberg,AE;Weaver,DL;Leslie,KO;Mann,KG;Taatjes,DJ;Tracy,RP
骨肉瘤（OSA）在组织学上很难与具有显著不同生物学潜能和治疗方案的肿瘤区分开来。OSA的正确诊断依赖于能够产生肿瘤性骨的恶性成骨细胞的鉴定。为了确定免疫组化在OSA诊断中的应用，对来自马萨诸塞州总医院和佛蒙特大学的106例肿瘤进行了单克隆抗骨钙素（OC）和抗骨粘连蛋白（ON）抗体免疫染色。其中包括42例骨肉瘤，25例非骨形成肉瘤，24例其他恶性肿瘤，包括淋巴瘤，癌和黑色素瘤，15例良性骨肿瘤。OC胞浆染色显示70%的敏感性和100%的特异性，而ON染色显示90%的敏感性和54%的特异性，骨形成肿瘤，一致染色细胞类型以外的成骨细胞。在OSA中，83%的患者表现出一种或两种抗体的基质染色，而在所有肿瘤中，两种抗体的致密胶原均为阴性。我们得出结论，单克隆OC的肿瘤细胞胞质染色可能有助于区分OSA与其他恶性肿瘤，同时OC和ON抗体的细胞外基质染色可能有助于区分骨基质与致密胶原。
Osteosarcomas (OSAs) can be difficult to distinguish histologically from tumors with significantly different biologic potentials and treatment protocols. The correct diagnosis of OSA relies on identification of malignant osteoblasts that are capable of producing neoplastic bone. To determine the use of immunohistochemistry for the diagnosis of OSA, 106 tumors from the Massachusetts General Hospital and the University of Vermont were immunostained with monoclonal antiosteocalcin (OC) and antiosteonectin (ON) antibodies. They included 42 OSAs, 25 non-bone-forming sarcomas, 24 other malignant tumors including lymphomas, carcinomas, and melanomas, and 15 benign bone tumors. Cytoplasmic staining with OC showed 70% sensitivity and 100% specificity, while staining with ON showed 90% sensitivity and 54% specificity for bone-forming tumors, consistently staining cell types other than osteoblasts. Of the OSAs, 83% demonstrated matrix staining with one or both antibodies, whereas dense collagen was negative for both antibodies in all tumors. We conclude that tumor cell cytoplasmic staining with monoclonal OC may be helpful in distinguishing OSAs from other malignancies, and staining of extracellular matrix for OC and ON antibodies concurrently may help distinguish bone matrix from dense collagen.